Article Information
- Received September 4, 1997
- Revision received October 23, 1997
- Accepted November 10, 1997
- First published February 1, 1998.
- Version of record published February 1, 1998.
Author Information
- David S. Park1,
- Erick J. Morris3,
- Leonidas Stefanis1,2,
- Carol M. Troy1,
- Michael L. Shelanski1,
- Herbert M. Geller3, and
- Lloyd A. Greene1
- 1Department of Pathology, Taub Center for Alzheimer’s Disease Research, and
- 2Neurology and Center for Neurobiology and Behavior, Columbia University College of Physicians and Surgeons, New York, New York 10032, and
- 3Department of Pharmacology, University of Medicine and Dentistry of New Jersey (UMDNJ)–Robert Wood Johnson Medical School, Piscataway, New Jersey 08854
Author contributions
Disclosures
- Received September 4, 1997.
- Revision received October 23, 1997.
- Accepted November 10, 1997.
This work was supported in part by Grants from National Institutes of Health (NS33689), March of Dimes, Blanchette Rockefeller Foundation, Amyotrophic Lateral Sclerosis Foundation, and the Aaron Diamond Foundation (to L.A.G.); by Grants NS36443 and ES06897 from National Institutes of Health and grants from the Cancer Institute of New Jersey (to H.M.G.) and from Muscular Dystrophy Association (to C.M.T.). DSP is an Aaron Diamond Foundation Fellow. We thank Dr. Peter J. Worland for kindly donating flavopiridol and for his helpful discussions.
Correspondence should be addressed to Dr. David S. Park, Department of Pathology, Taub Center for Alzheimer’s Disease Research, Columbia University College of Physicians and Surgeons, 630 West 168th Street, New York, NY 10032.
Online Impact